Ceibo Health Consulting的动态

The biggest fundamental driver in the sector... obesity ?? (part 1) When we meet with investors, the majority ask about the block-busting obesity drugs, and with good reason too. These drugs are transformative: for therapeutics innovation, revenue impact for the industry, and transformative for their consumers. We believe these will become the largest selling drugs in the industry. Looking at the sales potential, the key question is: will this market be $100 billion or $200 billion in 2030+? #Obesity #GrowthPortfolio #Innovation You can watch the AGM recording here ?? https://lnkd.in/eZZw43zW September factsheet: WWH_Factsheet_September_2024.pdf Find out more here: https://lnkd.in/eRNN7UZ6 Investments involve risks. The value of investments and income derived from them may go down as well as up and you may not receive back all the money which you invest. Past performance is no guarantee of future performance.

US Rare Disease Biotech leaders: A quick 5-minute read on leveraging HTA assessments to strengthen your US payer negotiations. https://lnkd.in/ewC8CKt7 Follow Partner Rare for more bite-sized insights. If you're approaching a new Rare Disease project, get in touch - no pressure, just helpful expertise. ?? #raredisease #biotech #pharma #HTA #marketentry #FDA #EMA #PartnerRare

Today is #RAREDISEASEDAY. JJP Biologics is committed to bringing #equity for people living with rare diseases by developing innovative and personalized treatments. ? A great example of JJP Biologics' commitment to bringing innovative and personalized treatments to patients with rare diseases is our lead program JJP-1212. In 2022 we received an orphan drug designation from the European Commission to develop JJP-1212 for the treatment of the ultra-rare autoimmune blistering disease linear IgA bullous dermatosis (LABD). ? LABD not only results in painful blisters that can lead to secondary infections and even blindness, it also leaves many patients with mental health challenges that affect them and their families. LABD currently has no approved therapies, leaving doctors with only sub-optimal offlabel used therapeutics as an option for treatment. ? Be a #SMARTGOOSE and stay tuned to our progress by following us here on Linkedin. To learn more about JJP Biologics and our innovation, please visit www.jjpbiologics.com #health #innovation

Interesting overview on recent pharma deals - In recent years, Big Pharma has made significant investments in promising areas like antibody-drug conjugates, radiopharmaceuticals, and obesity drugs. Fierce Pharma has tracked the most notable mergers and acquisitions, highlighting deals that have led to exciting clinical outcomes, like Novartis' acquisition of Chinook, or are on the verge of groundbreaking approvals, such as Bristol Myers Squibb's efforts. Companies like Roche and Carmot are exploring new treatment combinations with their acquired assets. The focus also includes market leaders like Novo Nordisk and Eli Lilly, whose strategic deals hint at future directions in the biopharma industry. https://lnkd.in/eg5xPJii

?? Recent developments in obesity treatment: A significant clinical trial ?? A noteworthy clinical trial is currently underway, comparing the efficacy of Retatrutide and Tirzepatide. This direct comparison has the potential to significantly improve weight management strategies. Key trial details: ? 800 participants ?? ? No placebo control group ? ? 90-day washout period required ? Both pharmaceuticals demonstrate considerable promise. However, their comparative effectiveness remains to be determined. ?? Tirzepatide: GIP/GLP-1 receptor agonist ?? Retatrutide: Triple agonist (GIP/GLP-1/Glucagon) ?????? The glucagon receptor activation in Retatrutide may be instrumental in achieving enhanced weight loss outcomes. The question remains whether this will result in superior performance compared to Tirzepatide. ???♀? Could Retatrutide represent a significant advancement in obesity treatment? ?? #ObesityMedicine #ClinicalTrials #PharmaceuticalInnovation #WeightManagement

An experimental long-acting steroid developed by Canadian biotech EuPRAXIA Pharmaceuticals has demonstrated initial success in relieving arthritis knee pain for an extended period of up to 14 weeks. In a mid-stage trial, a single injection significantly reduced knee pain and improved function for months, outperforming standard steroid treatments that typically last only 1-2 weeks. With minimal impact on blood sugar and hormone levels, this new treatment offers hope to millions suffering from osteoarthritis. A Phase III trial is already underway. Read the published results here: https://lnkd.in/eszidYjn #Osteoarthritis #BiotechInnovation #PainManagement #SteroidTherapy #Healthcare

Scleroderma - What's new on the horizon? ?? Systemic Sclerosis (SSc), known as scleroderma, is a rare rheumatic disease impacting multiple systems, characterized by skin inflammation and fibrosis ?? With two forms, including limited and diffuse cutaneous SSc, understanding its pathophysiology remains a challenge. Raynaud’s phenomenon occurs in over 95% of cases ?? SSc's global prevalence is 75,000 in the USA, 90,000 in Europe, and 28,000 in Japan. Despite its high mortality rate and lack of approved therapies, the potential market opportunity is significant, especially if clinical data supports effective treatments ?? Recent clinical trial setbacks highlight the complexities in drug development, but a disease-modifying drug for dcSSc patients could yield over $2 billion in revenue across the USA, EU, and Japan #scleroderma #AutoimmuneDisorder #perspectives #eosintelligence #healthcare #strategy #pharmaceuticals #biotech #competitiveintelligence #marketresearch ---------------------------------------------------------------------- Looking for in-depth insights into the rapidly evolving autoimmune disorders treatment market? Interested in key factors like catalysts, financial metrics, partnerships, pricing and reimbursement data to inform your decision-making? EOS Intelligence can help! Share your perspectives and challenges with us at [email protected]. We've got you covered!

?? ?? We are proud to announce alongside N-Zyme Biomedical Inc. that we are developing the World's First Pepsin Inhibitor for Reflux Disease—an innovative treatment option aimed at tackling acid reflux at its core. ???? Sometimes, even existing treatments aren’t enough. New solutions are needed to address chronic symptoms of GERD and Laryngopharyngeal Reflux (LPR). We're committed to developing customer-centric solutions in clinical care and addressing unmet needs in the #pharma industry. We're honored to be the outsourcing CDMO partner with #NZymeBiomedical, as it marks an exciting step forward for Reflux Disease patients. Learn more about this innovative drug development: https://bit.ly/4eE7lyq #GERDRelief #InnovationInHealth #RefluxDisease #CDMOs #CDMOPartner #MedicalTreatments

“This must be too small to be of any importance!” Have you ever considered not bringing up the “small little thing” that bothered you, at work or in life? What if that “small little thing” ends up being worth billions of dollars? Clinical trials are full of accidental discoveries: drugs that are meant to solve one problem turn out to work amazingly well, or better yet, for another. The most famous one is of course Viagra, initially investigated for cardiovascular diseases.?? Zyban - a drug originally meant to treat depression, has a side effect of patients stopping smoking. The cigarettes didn’t quite taste right during the treatment.?? The recent blockbuster - Ozempic - originally intended to help diabetic patients, found a much broader use as a weight loss drug. Cases like that could never have been discovered if it wasn’t for patient feedback: bringing up the “small little thing” that bothered them. These discoveries only happened because enough clinical trial participants complained, because an investigator listened, and because a study coordinator entered it into the study documentation. So the next time you’re thinking that “this must be too small to be of any importance”or even “I’m too embarrassed to bring it up” think about the patient in the cardiovascular study that brought up sildenafil’s side effect and forever changed the pharmaceutical industry. ????♂? #accidentaldiscoveries #raiseyourhand #drugdevelopment